TCEA2

Across TCGA pan-cancer cohorts, TCEA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCEA2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TCEA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TCEA2 expression acts as an unfavorable survival marker, although some lineages such as OV and LUAD show a favorable association.

OV, LUAD, and UCEC are the cancer types where TCEA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.942	0.556	.015	8	view →
LUAD	DFS	Quartile	All	0.710	0.348	.018	6	view →
UCEC	OS	Median	All	0.868	0.978	.028	6	view →
HNSC	DFS	Median	All	0.470	0.754	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCEA2–OV (DFS)

Open the OV breakdown →